Skip to content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study

  • Samer Hammoudeh1,
  • Suhaila Ghuloum2,
  • Ziyad Mahfoud3,
  • Arij Yehya1,
  • Abdulmoneim Abdulhakam2,
  • Azza Al-Mujalli4,
  • Mahmoud Al-Zirie5,
  • Mohamed Osman Abdel Rahman6,
  • Angela Godwin6,
  • Noura Younes6,
  • Yahya Hani2,
  • Dennis Mook-Kanamori7,
  • Marjonneke Mook-Kanamori7,
  • Reem El Sherbiny1 and
  • Hassen Al-Amin8Email author
BMC PsychiatryBMC series – open, inclusive and trusted201818:81

https://doi.org/10.1186/s12888-018-1662-6

Received: 8 March 2017

Accepted: 13 March 2018

Published: 27 March 2018

Abstract

Background

Metabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on antipsychotics relative to controls in Qatar, and to assess the factors contributing to the development of MetS.

Methods

A cross sectional design was used to collect data and fasting blood samples from subjects maintained on antipsychotics for at least six months (n = 112) and from a control group (n = 114). The groups were compared in regard to prevalence of MetS, and multiple regression analysis was used to determine the risk factors in each group.

Results

The two groups (antipsychotics vs. control) were similar in regard to age (35.73 ± 10.28 vs. 35.73 ± 8.16 years) and gender ratio. The MetS was higher among the subjects on antipsychotics, but this difference did not reach statistical significance. Blood pressure (BP) was significantly higher in the antipsychotics group and BMI was the major risk factor to develop MetS in this group.

Conclusions

The prevalence of MetS in both groups is high and mostly attributed to obesity and high BP. Public health interventions are needed to address this major health problem overall. Larger studies are needed to further assess the impact of antipsychotics and mental illness on the development of MetS.

Keywords

Metabolic syndromeAntipsychoticsArabsMental illness

Background

Metabolic syndrome (MetS) comprises specific risk factors for cardiovascular disease. These factors are increased waist circumference, raised fasting glucose, hypertension, and dyslipidemia. Several organizations have established criteria for the identification of MetS such as the National Cholesterol Education Program/Adult Treatment Panel III (ATP III) or International Diabetes Federation (IDF) [1]. Chronic mental disorders like schizophrenia and bipolar disorder have been associated with higher prevalence of MetS [2, 3], which is contributing to the increased rates of mortality and morbidity in these patients [2]. Antipsychotics are also known to cause weight gain and increase in glucose or cholesterol levels [46], which also increase the prevalence of MetS.

Both groups of antipsychotics, first generation antipsychotics (FGA) and second generation antipsychotics (SGA), are indicated for the treatment of schizophrenia [7]. Many SGA are also indicated for bipolar disorder [8] and as augmentation for resistant depression [9]. The metabolic side effects are more frequently seen with SGA than with FGA [10]. Several studies have shown that SGA have differential risk on weight gain and MetS with clozapine and olanzapine demonstrating the highest risk while ziprasidone and aripiprazole have the lowest [11, 12]. However, other studies from Japan [13], Venezuela [14], and Italy [15] did not show that antipsychotics increase the risk of MetS compared to control subjects. Bajaj et al. (2013) showed a positive correlation between the duration of treatment and the prevalence of MetS among those taking SGA [16]. In addition, Gautam and Meena (2011) reported that 11.66% of the patients with schizophrenia developed MetS after four months of being on antipsychotics [17]. Thus, it seems that there are racial and cultural differences when studying the prevalence of MetS in patients with schizophrenia and maintained on antipsychotics.

In the Arab countries, several studies have suggested higher prevalence of MetS in these populations [1821]. For example, in Qatar, Bener et al. [22] reported a MetS prevalence rate among the general population of 26.2% and 36.9% based on ATP III and IDF criteria, respectively. A cross sectional study, which looked into obese subjects attending primary health care centers in Qatar showed an overall prevalence rate of 46.3% (IDF criteria) [23]. The few prevalence studies conducted in the Arab countries on mental illness and MetS have shown similar results but mostly these were either retrospective starting with the patients with mental illness or without a control group. A Lebanese study reported a prevalence rate of MetS among schizophrenia patients on SGA of 32.3% (ATP III criteria) and of 48.4% (IDF criteria) [24]. A Kuwaiti study on schizophrenia inpatients showed prevalence rates of 18.8%, 23.2%, and 24.9% according to the ATP III, American Heart Association/National Heart, Lung, and Blood Institute (AHA/ATP III-A), and IDF definitions, respectively [25]. Severity and duration of illness, along with age, were reported as factors that correlate with increased prevalence of MetS [25]. Similarly, a cross sectional study reported a MetS prevalence rate of 43.6% among schizophrenia Palestinian patients according to the ATP III definition [26]. A cross sectional study in the United Arab Emirates (UAE) reported MetS (ATP III criteria) prevalence rates of 58.9%, 44.2% and 34.2% among patients with schizophrenia, bipolar disorder and major depression, respectively. The same study reported the following as factors that are more common in patients with MetS: advanced age, obesity, female gender, history and/or family history of diabetes, longer duration of mental illness and of psychotropic treatment [27]. None of the above studies had a control group to judge if the high prevalence of MetS is different from that in the general population to conclude that the mental illness and the psychotropics are implicated in this high prevalence of MetS. One previous study from Qatar assessed patients with schizophrenia and showed a significantly higher prevalence of MetS (ATP III criteria) when compared to control subjects not receiving antipsychotics and with no mental illness (36.5% vs. 18.7%) [28]. Central obesity was the most commonly encountered risk factor among patients with schizophrenia compared to controls (63.9% vs. 45.7%) [28]. This study also included schizophrenia patients only, and thus few studies in the Arab countries have assessed directly the association of antipsychotics with MetS.

The aim of this cross-sectional study in Qatar was to compare the prevalence of Mets in subjects maintained on antipsychotics for at least six months vs. controls with no mental illness and not taking antipsychotics. We hypothesized that those taking antipsychotics will have higher prevalence of MetS. A secondary analysis was done to determine the factors contributing to having MetS in our sample.

Methods

Setting and participants

Qatar is a rapidly growing country where Qataris and other Arabs are about 25% of the general population while the others are expatriates from many different countries especially from south Asia. A total of 226 participants were recruited between December 2012 and June 2014. Patients maintained on antipsychotics (n = 112) were recruited from the Psychiatry Department at Rumailah hospital, Doha, Qatar. This department is the only psychiatric facility in Qatar. The control subjects (n = 114) were recruited from the Primary Health Care Center, Doha, Qatar and the patients’ visitors at the Department of Psychiatry. The treatment teams at both facilities screened the subjects using convenience sampling and invited those who were eligible according to the inclusion and exclusion criteria presented below. About 74% of the eligible subjects for the antipsychotics group agreed to participate and about 68% from those eligible for the control group were enrolled (see the flow chart in Fig. 1).
Figure 1
Fig. 1

Flow chart showing the number of subjects screened, eligible, completed the assessments and the final number used in the analysis

The inclusion criteria for patients on antipsychotics were: (a) 18–65 years of age, (b) have been taking antipsychotics for at least the last six months, (c) not known to have MetS and (d) able to sign a consent form. The exclusion criteria were: (a) have been taking Lithium, Nortriptyline or Amitriptyline for the past three months as these medications are associated with significant weight gain and (b) have current substance abuse or dependency disorder. The psychiatric diagnosis of these subjects was obtained from the patients’ records and relied on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria at that time. The inclusion and exclusion criteria for the control group were the same as the antipsychotics group except that subjects had not received any antipsychotics. The control subjects were screened using the Mini International Neuropsychiatric Interview (MINI-6) to make sure that they have no psychiatric disorder. Approval for the study was obtained from Hamad Medical Corporation (HMC) and Weill Cornell Medicine-Qatar (WCM-Q) Institutional Review Boards. All participants signed a written informed consent after they received clear information about the study and the duration of procedures.

Sample size calculation

With 75 cases (patients receiving antipsychotics) and 75 controls (general population) matched for age and gender, we expected to detect a difference of 26% in the prevalence of MetS between cases and controls, with a power of 90% and a significance level of 5%. These calculations were done using the proportion of MetS of 26% among the general population [29] and postulating a two-fold increase in the rate of MetS among patients taking antipsychotics as compared to the general population [30]. As the difference in the prevalence might not be as large as in other populations and to allow for subgroup analyses we elected to recruit 110 patients and 110 controls. This will allow us to detect a smaller difference of about 20% between the two groups. The numbers recruited are slightly higher as we had some incomplete data on few subjects.

Diagnosis of MetS

Two diagnostic criteria for MetS were used in this study. The ATP III criteria [31] and the IDF criteria [32], which are shown in Table 1.
Table 1

Summary of the ATP III and IDF criteria for MetS

 

ATP III (3 of 5)

IDF (2 of 4, central obesity is mandatory)

Waist circumference

Abdominal obesity, based on waist circumference > 102 cm for men, and > 88 cm for women

Central obesity based on ethnicity specific valuesa (for Europids: waist circumference ≥ 94 cm for men, and ≥ 80 cm for women).

Triglycerides

≥ 150 mg/dL

≥ 150 mg/dL, or specific treatment for this lipid abnormality.

HDL cholesterol

<  40 mg/dL for men

<  50 mg/dL for women

<  40 mg/dL for men, <  50 mg/dL for women, or specific treatment for this lipid abnormality.

Blood pressure (BP)

≥ 130/ ≥85 mmHg

Systolic BP ≥ 130 mmHg, or diastolic BP ≥ 85 mmHg, or treatment of previously diagnosed hypertension.

Fasting glucose

≥ 110 mg/dL

≥ 100 mg/dL, or previously diagnosed type 2 diabetes mellitus.

aEuropean measures were used due to the lack of regional standards. ATP III: Adult Treatment Panel III. IDF: International Diabetes Federation. MetS: Metabolic syndrome. HDL: High-density lipoproteins

Procedures and measurements

The questionnaires covered the following categories: sociodemographic data, medical/psychiatric history, family history and type/duration of antipsychotics intake. The vital signs (blood pressure and heart rate using General Electric Critikon Dinamap Pro 400 V2) and anthropometric measurements (height, weight, waist and hip circumference using Seca instruments) were obtained from all participants. The waist circumference was measured at the level midway between the lowest rib and the iliac crest.

Four raters were trained to administer these validated questionnaires and measures according to specific standardized operating procedures. The raters applied the same procedures to both the active and control subjects within 1–2 days after obtaining the informed consent. The subjects were then asked to be present, within 1–2 days, to draw blood samples after fasting for 10–12 h. All the blood tests (CBC, lipid profile, HbA1c, fasting glucose, liver and kidney function tests) were done according to the same standardized procedures of the laboratories of Rumailah hospital, Doha, Qatar.

Statistical analysis

All statistical analyses were conducted using the Statistical Product and Service Solutions (SPSS) version 23. The level of significance was set at 0.05 level. Descriptives were reported using frequency (percentage) for categorical variables and mean ± SD (or interquartile range) for continuous measures respectively. To compare groups, chi square test was used to analyze categorical variables and independent two-tailed t-test was used with continuous variables. Bivariate analysis (antipsychotics vs. control) was conducted to compare the sociodemographic and clinical characteristics of the two groups. We also did bivariate analysis for each group separately looking at the differences between those with MetS and those without (MetS vs. no MetS). The Kolmogorov-Smirnov test was used to assess normality. In this regard, Mann-Whitney U was used. All bivariate analyses were done with Bonferroni corrections for multiple comparisons. In order to assess the factors that are contributing to having MetS in each of the groups (antipsychotics or controls), multiple logistic regression (backward conditional, as this is an exploratory approach) was done, separately for each group, using the significant variables from the bivariate analysis (MetS vs. no MetS). The best-fit model was tested using Hosmer and Lemeshow test and by checking Cox and Snell R2 and Nagelkerke R2.

Results

Sociodemographic and medical characteristics

There were no significant differences between the two groups in regard to age or gender (Table 2). When compared to the control group, the patients on antipsychotics had significantly higher number of Qataris/Arabs, single individuals, and unemployed participants with school education only. In the control group the significant majority were Non-Arabs, married, never smoked, college graduates and employed (Table 2). The Arab population included the following countries: Algeria, Egypt, Jordan, Kuwait, Lebanon, Libya, Morocco, Palestine territories, Qatar, Kingdom of Saudi Arabia, Somalia, Sudan, Syria, Tunisia and Yemen. The Non-Arabs were mostly from south Asia (Bangladesh, India, Nepal, Pakistan, and Sri Lanka) and sporadic cases from France, Iran, Nigeria, Kenya, Tanzania, Philippines and United States. In regard to medical history there were significantly more smokers in the antipsychotics group. Furthermore, there were no significant differences between the two groups in the blood count measures, liver, kidney and thyroid function tests.
Table 2

Sociodemographic and medical characteristics of study participants by group

Variables

Antipsychotics group (n = 112)

Control group (n = 114)

Age (mean ± SD)

35.73 ± 10.28

35.73 ± 8.16

Gender n (%)

 Male

 Female

73 (65.2%)

39 (34.8%)

69 (60.5%)

45 (39.5%)

Ethnicity n (%)

 Qataris and Arabs

 Non-Arabs

79 (71.2%)*

32 (28.8%)

52 (45.6%)

62 (54.4%)**

Marital status n (%)

 Married

 Single

 Divorced

43 (38.4%)

57 (50.9%)*

12 (10.7%)*

83 (72.8%)**

30 (26.3%)

1 (0.9%)

Degree n (%)

 None

 School

 Vocational

 College/graduate

4 (3.6%)

72 (64.3%)*

7 (6.3%)

28 (25.0%)

4 (3.5%)

45 (39.5%)

15 (13.2%)

49 (43.0%)**

Employment n (%)

 Employed

 Not employed

 Other (student, retired, etc.)

41 (36.6%)

62 (55.4%)*

9 (8%)

103 (90.4%)**

9 (7.8%)

2 (1.8%)

Smoking/current n (%)

 Yes

 No

40 (36.7%)*

69 (63.3%)

18 (18%)

82 (82%)**

Smoking/ever n (%)

 Yes

 No

52 (47.3%)*

58 (52.7%)

26 (22.8%)

88 (77.2%)**

History of Diabetes n (%)

 Yes

 No

9 (8.2%)

101 (91.8%)

8 (7.3%)

101 (92.7%)

Family history of diabetes n (%)

 Yes

 No

74 (66.1%)

38 (33.9%)

74 (64.9%)

40 (35.1%)

Body mass index (BMI)

(mean ± SD)

29.12 ± 6.95

27.74 ± 5.05

*Higher than the control group; **Higher than the antipsychotics group (p < 0.05)

Psychiatric profile of the antipsychotics group

Patients who were on antipsychotics had mainly the following three diagnoses: bipolar (42.0%), schizophrenia/schizoaffective (35.7%), and depression (7.1%). The remaining 15.2% included the following disorders: personality, obsessive compulsive, delusional, psychotic not otherwise specified or mood not otherwise specified.

The majority had history of multiple hospitalizations and were on SGA, where 43 subjects (38.4%) were on olanzapine, 36 on risperidone (32.1%), 17 on aripiprazole (15.2%), 12 on quetiapine (10.7%), 6 on paliperidone (5.4%), and 3 on clozapine (2.7%). In regard to FGA, 3 were on flupenthixol (2.7%), 4 on trifluoperazine (3.6%), 15 on haloperidol (13.4%), and 16 on chlorpromazine (14.3%). It is worth noting that 21 patients were on a combination of FGA and SGA, and few others were receiving more than two antipsychotics. As many patients received multiple antipsychotics throughout the duration of their illness we calculated also the mean duration of the last antipsychotic received, which was over a year (Table 3).
Table 3

Clinical characteristics of patients maintained on antipsychotics

Antipsychotics group (n = 112)

Frequency

Percentage

Type of antipsychotic

 FGA

 SGA

 Combination of both

15

76

21

13.4%

67.9%

18.8%

Hospitalized before

 Yes

 No

82

30

73.2%

26.8%

Suicide attempt

 Yes

 No

26

80

23.2%

71.4%

 

Mean

SD

Duration of illness (years)

12.6

9.37

Number of Hospitalizations

4.12

4.02

Total psychotropic medications taken/lifetime

4.36

2.81

 

Mean

IQRa

Dose of antipsychoticsb

689.52

405.39

Duration of last psychotropic medication (months)

15.86

12

aIQR: Interquartile range, bChlorpromazine 100 mg/day equivalent doses for antipsychotics [33]

Prevalence of MetS

The prevalence of MetS was higher in the antipsychotics group (31.9% for ATP III and 35.4% for IDF criteria) when compared to the control group (22.8% for ATP III and 29.8% for IDF criteria) (Fig. 2). However, this increase did not reach statistical significance, p = 0.12 for ATP III and p = 0.37 for IDF.
Figure 2
Fig. 2

Metabolic syndrome (MetS) prevalence rates among participants based on the ATP III and IDF criteria. Patients with mental illness who were maintained on antipsychotics (n = 112) for at least 6 months were compared to a control group (n = 114). No significant difference in the prevalence of MetS between the two groups. ATP III: Adult Treatment Panel III. IDF: International Diabetes Federation

A comparison between the groups on the different metabolic factors is shown in Table 4. Systolic (p = 0.001) and diastolic (p < 0.001) blood pressures (BP) were significantly higher in the antipsychotics group.
Table 4

Distribution of MetS factors (Mean ± SD) by group

MetS factor

Antipsychotics group

(n = 112)

Control group (n = 114)

Triglycerides (mg/dL)

1.60 ± 1.05

1.54 ± 0.99

HDL (mg/dL)

1.22 ± 0.32

1.20 ± 0.44

Fasting plasma glucose (mg/dL)

6.28 ± 4.94

5.72 ± 2.16

Systolic BP (mmHg)

127.69 ± 13.70*

120.87 ± 15.22

Diastolic BP (mmHg)

81.29 ± 10.75*

75.49 ± 12.40

Waist circumference (cm)

97.16 ± 14.09

99.03 ± 92.29

*Higher than the control group (p < 0.05). HDL: High-density lipoproteins

Biopsychosocial profile and MetS

Bivariate analysis of the sociodemographic and clinical characteristics in the antipsychotics group alone showed that participants with MetS (vs. no MetS) had longer duration of illness (p < 0.05, ATP and IDF) and increased duration of treatment with the last antipsychotic (p < 0.05, ATP); they were also older (age, p < 0.05, ATP), mostly Arabs (χ2 = 3.91, p = 0.048, IDF), obese (BMI, p < 0.05, ATP and IDF), known to have diabetes (χ2 = 5.49, p = 0.02, IDF) and current smokers (χ2 = 4.10, p = 0.04, IDF). There were no significant differences in regard to gender, marital status, diagnosis, type, number or equivalent dose of antipsychotics. The same analysis in the control group showed that the following factors were significantly more common in the subjects with MetS: older age (p < 0.05, ATP and IDF), being male (gender, χ2 = 5.16, p = 0.02, IDF), non-Arab (ethnicity, χ2 = 7.16, p = 0.007), obesity (BMI, p < 0.05, IDF), having diabetes (χ2 = 4.33, p = 0.04, ATP) and current smokers (χ2 = 4.43, p = 0.04, ATP). The other demographic and medical features were not significant.

Multiple regression analysis and MetS

A multiple logistic regression (backward conditional) was carried out for each group separately using the significant factors from the above bivariate analyses to assess what factors are independently contributing to the presence of MetS (as per IDF criteria that gave more people with MetS) in each group. The predictors in the control group were age, gender, ethnicity, BMI, history of diabetes and currently smoking. The same variables were added in the analysis of the antipsychotics group in addition to the duration of psychiatric illness and duration of last antipsychotic treatment. We elected to add also the current dose of antipsychotics, as it is known to contribute to the metabolic effects.

In the control group the full regression model with all the six predictors was significant (χ2 = 26.95, df = 6, p < 0.001). The results of Cox and Snell R2, and Nagelkerke R2 showed that the model explained between 25% and 35% of the variance predicted by these independent factors. This best-fit model was ascertained by the Hosmer and Lemeshow test (χ2 = 3.44, df = 8, p = 0.91). The whole model gave an overall 77% correct rate of the outcome (MetS vs. no MetS). The predictors that remained significant after controlling for the other ones were: age (odds ratio: OR = 1.087, 95% confidence interval (CI): 1.015–1.363, p = 0.017), being non-Arab (OR = 9.693, 95% CI: 2.427–38.713, p = 0.001) and BMI (OR = 1.197, 95% CI: 1.054–1.359, p = 0.006).

In the antipsychotics group the full regression model was significant (χ2 = 17.85, df = 9, p < 0.037). The results of Cox and Snell R2, and Nagelkerke R2 showed that the model explained between 27% and 37% of the variance predicted by these independent variables. The Hosmer and Lemeshow test confirmed that this model is a good fit (χ2 = 8,57, df = 8, p = 0.38). The overall success rate in this model was also 77%. However, the only predictor that remained significant was the BMI (OR = 1.162, 95% CI: 1.047–1.289, p = 0.005).

Discussion

The aim of this cross-sectional study was to check the metabolic effects of antipsychotics when compared to a control group. The prevalence of MetS was not significantly different between the two groups but the systolic and diastolic BPs were significantly higher in the group receiving antipsychotics. However, a difference of 9% (ATP III) or 5% (IDF) in the prevalence rates of MetS is clinically relevant, but probably did not reach statistical significance because of the high prevalence of MetS in the general population in our study compared to other population studies [14, 19, 21]. In regard to the MetS prevalence in patients with mental illness, our rates are very close to the ones reported previously from Qatar [28], where the overall prevalence of MetS in schizophrenia patients was 36.5% vs. 31.9% (IDF criteria) in our study. However, in the same study the prevalence of MetS in the control group was 18.7%, which is very different from the prevalence reported in a population study from Qatar by the same group where the prevalence of MetS in the general population was 26.5% [29]. The prevalence rate of MetS in the antipsychotic group in our study (31.9%) is higher than rates reported on the Kuwaiti (18.8%) [25], but lower than the rates reported from UAE (58.9%) [27] and Palestinian patients with schizophrenia (43.6%) [26]. It is worth mentioning that these studies were basically on patients with specific diagnoses without taking into consideration the type of medications received and did not have a control group to compare with. As presented in the introduction [13, 14, 30] it seems that there are also differences among nations in the prevalence of MetS in the general population and in the degree of worsening of these metabolic factors with antipsychotics.

The high level of obesity among the general population in our study is probably what contributed to the high prevalence of MetS in our sample, as previous studies from the Arabic Gulf region [33] and from Qatar [34] showed high obesity rates. This is also supported by our results on multiple regression analyses where high BMI was a major risk factor to develop MetS in both groups. This also explains the difference in the prevalence rates of MetS based on the two different criteria used in this study, as the IDF definition mandates having central obesity to confirm MetS, in comparison to the ATP III criteria that do not.

Our results also showed significant differences in BP, when comparing the antipsychotics vs. control group. Hypertension is also known to be very common in the population of Qatar with a prevalence rate of 37.1% [34]. Although antipsychotics are known to cause mild orthostatic hypotension, the increased BP in patients on antipsychotics could be secondary to the increased weight gain as they had also higher BMI. Other studies using logistic regression models have shown that obesity is associated with hypertension as well as dyslipidemia [35]. Few case studies have reported increased BP with few antipsychotics [36, 37]. Still others suggested that maintenance on antipsychotics could lead to autonomic dysfunction (and increased adrenergic activity) and thus higher BP and more metabolic and cardiovascular effects [38].

When participants were compared based on the presence of MetS, several factors emerged as possibly contributing to the high prevalence of MetS in the general population. These factors are older age, being male, expatriate, smoker, having diabetes and obesity. Our regression analysis from the controls confirmed older age and higher BMI as risk factors for developing MetS in the general population of Qatar [29, 39] as have been shown in other countries [20, 21]. The former studies from Qatar also showed that females are more at risk to have MetS, but in our study gender was not a risk factor, probably because the majority of our sample were males. It is worth noting that the majority of the population in Qatar is men (75%) as many workers migrate to Qatar without their families. However, the studies from other countries reported mixed results in regard to gender [21, 35, 40]. Furthermore, our study also showed that being of non-Arab origin was a risk factor for developing MetS. The majority of non-Arabs were from south Asia but the numbers from the different countries were small to warrant statistical comparison. It is worth noting that in our sample there were more Arabs in the antipsychotics group while in the control group the majority were non-Arabs, which could explain this variability between the two groups. Still ethnicity/nationality showed significant variations in the prevalence of MetS in patients with mental illness and maintained on antipsychotics [5, 13, 14, 2427].

In addition, for the group on antipsychotics, longer duration of illness and of maintenance on current antipsychotics are probably also contributing to the presence of MetS in the patients on antipsychotics. In this group, regression analysis showed obesity as a risk factor to develop MetS. A study on Han Chinese patients with schizophrenia had also demonstrated high BMI as an independent risk factor to develop MetS [40]. Similar findings were reported in a prospective study on patients with bipolar disorder from Italy where older age, higher BMI and exposure to antipsychotics were independently associated with the risk of developing MetS after two years [41]. The study on Palestinian patients with schizophrenia showed also higher prevalence of MetS in patients who are older, with abdominal obesity, longer duration of illness, smoking and with high BP, except for being more prevalent in females in their study. However, none of these sociodemographic features were significant in regression analysis [26]. Contrary to the general belief that SGA are more associated with MetS [11, 12], others have shown that polypharmacy and type of antipsychotics were not associated with increased risk of MetS in patients maintained on antipsychotics [42, 43]. Our results did not find any significant differences between those with MetS vs. not when comparing the type of antipsychotics and equivalent doses of antipsychotics.

This prevalence study has several strengths like the cross-sectional design, having a control group with similar protocols of assessment, trained research staff and the focus on the effects of antipsychotics. However, there are limitations that might limit the interpretation of findings like the sample size, the preponderance of males in the sample recruited, the unequal representation of the different nationalities and the large variability in the duration of illness and dosage of medications, as these factors can affect the severity of the metabolic effects of antipsychotics and should be controlled for in future studies.

Conclusions

Our results showed that the prevalence of MetS is high in both the control group and the patients on antipsychotics in Qatar. The major risk factor and contributor to this increase is the high prevalence of obesity in this region. BP was the only constituent of MetS that was significantly higher in patients maintained on antipsychotics. Both groups can benefit from interventions to reduce weight gain and control high BP especially with longer duration of illness and maintenance on antipsychotics.

Abbreviations

AHA: 

American Heart Association

ATP III: 

Adult Treatment Panel III

BMI: 

Body Mass Index

BP: 

Blood Pressure

DSM IV: 

Diagnostic and Statistical Manual of Mental Disorders, version four

FGA: 

First Generation Antipsychotics

HDL: 

High-density lipoproteins

HMC: 

Hamad Medical Corporation

IDF: 

International Diabetes Federation;

IQR: 

Interquartile Range

MetS: 

Metabolic Syndrome

MINI: 

Mini International Neuropsychiatric Interview

QNRF: 

Qatar National Research Fund

SGA: 

Second Generation Antipsychotics

SPSS: 

Statistical Product and Service Solutions

UAE: 

United Arab Emirates

WCM-Q: 

Weill Cornell Medicine-Qatar

Declarations

Acknowledgments

Not applicable.

Funding

This study was part of a larger project funded solely by Qatar National Research Fund (QNRF) www.qnrf.org <http://www.qnrf.org> granted to Dr. Hassen Al-Amin (NPRP 4–268–3-085). QNRF did not have any additional role in the study design, data collection and analysis, interpretation of data, decision to publish, or preparation of the manuscript.

Availability of data and materials

In order to protect the privacy and confidentiality of the research participants our de-identified data are available only upon request and after compliance with the policies and procedures of WCM-Q, HMC and Qatar National Research Fund (QNRF) for data sharing. Requests can be submitted to Hassen Al-Amin at haa2019@qatar-med.cornell.edu.

Authors’ contributions

SH contributed to data collection, interpretation and wrote the first draft of the manuscript. SG contributed to study design and conduct at the hospital. ZM and AY contributed to statistical analysis, data interpretation and finalizing the results. AA contributed to study design and recruitment of subjects. AAM supervised the study progress at the primary health care center. MZ contributed to study design and conduct at the hospital. MOA contributed to the design of laboratory tests and interpretation of results. AG and NY supervised the conduct of the laboratory tests at the hospital. YH contributed to the preparation of research forms and data collection. DMK contributed to the preparation of research questionnaires. MMK contributed to study design and data interpretation. RE contributed to the administrative aspects and to data collection. HA is the principle investigator on this project, contributed to protocol and study design, data interpretation, manuscript writing and revisions, and supervised all study procedures. All authors read and approved this manuscript.

Ethics approval and consent to participate

Approvals for the study were obtained from Hamad Medical Corporation (HMC) and Weill Cornell Medicine-Qatar (WCM-Q) Institutional Review Boards. All participants signed a written informed consent before joining the study and after they received clear information about the study and the duration of procedures.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Research, Weill Cornell Medicine – Qatar, Doha, Qatar
(2)
Department of Psychiatry, Rumailah Hospital, Hamad Medical Corporation, Doha, Qatar
(3)
Department of Health Policy and Research, Weill Cornell Medicine – Qatar, Doha, Qatar
(4)
Primary Health Care Corporation, Doha, Qatar
(5)
Endocrinology Department, Hamad General Hospital, Doha, Qatar
(6)
Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar
(7)
Department of Physiology and Biophysics, Weill Cornell Medicine – Qatar, Doha, Qatar
(8)
Department of Psychiatry, Weill Cornell Medicine – Qatar, Doha, Qatar

References

  1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation. 2009;120(16):1640–5.PubMedView ArticleGoogle Scholar
  2. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339–47.PubMedPubMed CentralView ArticleGoogle Scholar
  3. Grover SNN, Padmavati R, Chadda R, Tirupati S, Pallava A. Metabolic syndrome in antipsychotic naiive patients with schizophrenia: pooled analysis of data from three Indian studies. Early Interv Psychiatry. 2014;9(5):357–62.PubMedView ArticleGoogle Scholar
  4. Demirel A, Demirel OF, Emul M, Duran A, Ugur M. Relationships between IGF-1, schizophrenia, and treatment of metabolic syndrome. Compr Psychiatry. 2014;55(6):1391–7.PubMedView ArticleGoogle Scholar
  5. Said MA, Hatim A, Habil MH, Zafidah W, Haslina MY, Badiah Y, et al. Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia. Prev Med. 2013;57(Suppl):S50–3.PubMedView ArticleGoogle Scholar
  6. Lambert T. Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis. Aust Prescr. 2011;34:97–9.View ArticleGoogle Scholar
  7. Treating schizophrenia: A quick reference guide. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia-guide.pdf. Accessed 15 Sep 2016.
  8. Practice guideline for the treatment of patients with bipolar disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf. Accessed 19 Aug 2016.
  9. Kato M, Chang CM. Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression. CNS Drugs. 2013;27(Suppl 1):S11–9.PubMedView ArticleGoogle Scholar
  10. Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects. http://www.uptodate.com/contents/second-generation-antipsychotic-medications-pharmacology-administration-and-comparative-side-effects. Accessed 17 Feb 2016.
  11. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169–79.PubMedView ArticleGoogle Scholar
  12. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Current opinion in endocrinology, diabetes, and obesity. 2010;17(5):460–6.PubMedView ArticleGoogle Scholar
  13. Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Tsuneyama N, et al. Low prevalence of metabolic syndrome and its prediction in Japanese inpatients with schizophrenia. Hum Psychopharmacol. 2013;28(2):188–91.PubMedView ArticleGoogle Scholar
  14. Baptista T, Serrano A, Uzcategui E, ElFakih Y, Rangel N, Carrizo E, et al. The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela. Schizophr Res. 2011;126(1–3):93–102.PubMedView ArticleGoogle Scholar
  15. Santini I, Stratta P, D'Onofrio S, De Lauretis I, Santarelli V, Pacitti F, Rossi A. The metabolic syndrome in an Italian psychiatric sample: a retrospective chart review of inpatients treated with antipsychotics. Riv Psichiatr 2016;51(1):37–42.Google Scholar
  16. Bajaj S, Varma A, Srivastava A, Verma AK. Association of metabolic syndrome with schizophrenia. Indian J Endocrinol Metab. 2013;17(5):890–5.PubMedPubMed CentralView ArticleGoogle Scholar
  17. Gautam S, Meena PS. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Indian J Psychiatry. 2011;53(2):128–33.PubMedPubMed CentralView ArticleGoogle Scholar
  18. Mabry RM, Reeves MM, Eakin EG, Owen N. Gender differences in prevalence of the metabolic syndrome in gulf cooperation council countries: a systematic review. Diabet Med. 2010;27(5):593–7.PubMedView ArticleGoogle Scholar
  19. Al Rashdan I, Al Nesef Y. Prevalence of overweight, obesity, and metabolic syndrome among adult Kuwaitis: results from community-based national survey. Angiology. 2010;61(1):42–8.PubMedView ArticleGoogle Scholar
  20. Aljohani NJ. Metabolic syndrome: risk factors among adults in Kingdom of Saudi Arabia. J Family Community Med. 2014;21(3):170–5.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Al-Lawati JA, Mohammed AJ, Al-Hinai HQ, Jousilahti P. Prevalence of the metabolic syndrome among Omani adults. Diabetes Care. 2003;26(6):1781–5.PubMedView ArticleGoogle Scholar
  22. Bener A, Darwish S, Al-Hamaq AO, Yousafzai MT, Nasralla EA. The potential impact of family history of metabolic syndrome and risk of type 2 diabetes mellitus: in a highly endogamous population. Indian J Endocrinol Metab. 2014;18(2):202–9.PubMedPubMed CentralView ArticleGoogle Scholar
  23. Ismail MF. Metabolic syndrome among obese Qataris attending primary health care centers in Doha, 2010. J Family Community Med. 2012;19(1):7–11.PubMedPubMed CentralView ArticleGoogle Scholar
  24. Bou Khalil R, Rohayem J, Abou said N, El Chammay R, Haddad R, Richa S. Metabolic syndrome (MetS) in Lebanese patients with schizophrenia receiving atypical antipsychotic drugs. Asian J Psychiatr. 2013;6(1):88–9.PubMedView ArticleGoogle Scholar
  25. Roshdy R. Prevalence of metabolic syndrome in patients with schizophrenia. Middle East Curr Psychiatry. 2011;18(2):109–17.View ArticleGoogle Scholar
  26. Sweileh WM, Zyoud SH, Dalal SA, Ibwini S, Sawalha AF, Ali I. Prevalence of metabolic syndrome among patients with schizophrenia in Palestine. BMC Psychiatry. 2012;12:235.PubMedPubMed CentralView ArticleGoogle Scholar
  27. Shahda M, Elsayed O, El-Boraie A. Study of the prevalence of metabolic syndrome among psychiatric patients and its correlation with diagnosis and medications. Egypt J Psychiatry. 2010;31(2):17–24.Google Scholar
  28. Bener A, Al-Hamaq AO, Dafeeah EE. A two fold risk of metabolic syndrome in a sample of patients with schizophrenia: do consanguinity and family history increase risk? Diabetes Metab Syndr. 2014;8(1):24–9.PubMedView ArticleGoogle Scholar
  29. Bener A, Zirie M, Musallam M, Khader YS, Al-Hamaq AO. Prevalence of metabolic syndrome according to adult treatment panel III and international diabetes federation criteria: a population-based study. Metab Syndr Relat Disord. 2009;7(3):221–9.PubMedView ArticleGoogle Scholar
  30. DEH M, Schreurs V, Vancampfort D, VANW R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8(1):15–22.View ArticleGoogle Scholar
  31. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004;24(2):e13–8.PubMedView ArticleGoogle Scholar
  32. The IDF consensus worldwide definition of the metabolic syndrome. https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html. Accessed 18 March 2018.
  33. Ng SW, Zaghloul S, Ali HI, Harrison G, Popkin BM. The prevalence and trends of overweight, obesity and nutrition-related non-communicable diseases in the Arabian gulf states. Obes Rev. 2011;12(1):1–13.PubMedView ArticleGoogle Scholar
  34. Bener A, Mohammad AG, Ismail AN, Zirie M, Abdullatef WK, Al-Hamaq AO. Gender and age-related differences in patients with the metabolic syndrome in a highly endogamous population. Bosn J Basic Med Sci. 2010;10(3):210–7.PubMedPubMed CentralView ArticleGoogle Scholar
  35. Susce MT, Villanueva N, Diaz FJ, de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry. 2005;66(2):167–73.PubMedView ArticleGoogle Scholar
  36. Borras L, Constant EL, Eytan A, Huguelet P. Hypertension and aripiprazole. Am J Psychiatry. 2005;162(12):2392.PubMedView ArticleGoogle Scholar
  37. Villanueva N, Markham-Abedi C, McNeely C, Diaz FJ, de Leon J. Probable association between ziprasidone and worsening hypertension. Pharmacotherapy. 2006;26(9):1352–7.PubMedView ArticleGoogle Scholar
  38. Scigliano G, Ronchetti G. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs. 2013;27(4):249–57.PubMedPubMed CentralView ArticleGoogle Scholar
  39. Musallam M, Bener A, Zirie M, Al-Gaud YK, Al-Hamaq AO, Othman M, Ihab T. Metabolic syndrome and its components among Qatari population. Int J food Saf Nutr. Public Health. 2008;1(1):88–102.Google Scholar
  40. Lin EC, Shao WC, Yang HJ, Yen M, Lee SY, Wu PC, et al. Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics? Metab Brain Dis. 2015;30(1):107–13.PubMedView ArticleGoogle Scholar
  41. Salvi V, D'Ambrosio V, Bogetto F, Maina G. Metabolic syndrome in Italian patients with bipolar disorder: a 2-year follow-up study. J Affect Disord. 2012;136(3):599–603.PubMedView ArticleGoogle Scholar
  42. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89(1–3):91–100.PubMedView ArticleGoogle Scholar
  43. Krane-Gartiser K, Breum L, Glumrr C, Linneberg A, Madsen M, Koster A, et al. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry. 2011;65(5):345–52.PubMedView ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement